Methallylescaline

Methallylescaline
Clinical data
Other names	MAL; 4-Methylallyloxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-methylallyloxyphenethylamine; 4-Methylallyl-desmethylmescaline; MAD
Routes of; administration	Oral
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics);
Pharmacokinetic data
Onset of action	≤1 hour
Duration of action	12–16 hours
Identifiers
	IUPAC name 2-{3,5-Dimethoxy-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}ethan-1-amine;
CAS Number	207740-41-8 ;
PubChem CID	44350127;
ChemSpider	21106346 ;
UNII	CVN0S9V910;
ChEMBL	ChEMBL126803 ;
CompTox Dashboard (EPA)	DTXSID20658380 ;
Chemical and physical data
Formula	C14H21NO3
Molar mass	251.326 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=C)COc1c(cc(cc1OC)CCN)OC;
	InChI InChI=1S/C14H21NO3/c1-10(2)9-18-14-12(16-3)7-11(5-6-15)8-13(14)17-4/h7-8H,1,5-6,9,15H2,2-4H3 ; Key:FOXJFBFFGULACD-UHFFFAOYSA-N ;
	(verify)

Methallylescaline (MAL), also known as 4-methylallyloxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is taken orally.

The drug acts as a serotonin 5-HT₂ receptor agonist, including of the serotonin 5-HT_2A receptor. It is closely structurally related to mescaline and to other scalines like escaline and allylescaline.

Methallylescaline was first described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). It was encountered as a novel designer drug by 2013.